Brokerages expect Clorox Co (NYSE:CLX) to announce $1.43 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Clorox’s earnings. The highest sales estimate is $1.43 billion and the lowest is $1.41 billion. Clorox posted sales of $1.41 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.4%. The business is expected to announce its next quarterly earnings results on Friday, February 2nd.

According to Zacks, analysts expect that Clorox will report full year sales of $1.43 billion for the current fiscal year, with estimates ranging from $6.11 billion to $6.16 billion. For the next fiscal year, analysts forecast that the business will report sales of $6.33 billion per share, with estimates ranging from $6.30 billion to $6.35 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Clorox.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. Clorox had a net margin of 11.84% and a return on equity of 161.59%. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.48 billion. During the same period last year, the company posted $1.36 EPS. Clorox’s revenue for the quarter was up 4.0% on a year-over-year basis.

A number of research firms recently issued reports on CLX. Jefferies Group reissued a “hold” rating and set a $130.00 target price on shares of Clorox in a research note on Wednesday. Wells Fargo & Company reissued a “hold” rating and set a $130.00 target price on shares of Clorox in a research note on Wednesday. Deutsche Bank began coverage on Clorox in a research note on Wednesday. They set a “hold” rating and a $142.00 target price for the company. BMO Capital Markets reissued an “outperform” rating on shares of Clorox in a research note on Tuesday, September 12th. Finally, Consumer Edge raised Clorox from a “neutral” rating to an “outperform” rating in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $129.05.

In other news, SVP Michael R. Costello sold 10,574 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the completion of the transaction, the senior vice president now directly owns 34,867 shares of the company’s stock, valued at approximately $4,742,260.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Matthew T. Laszlo sold 20,051 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the transaction, the senior vice president now directly owns 10,896 shares of the company’s stock, valued at $1,421,492.16. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Clorox by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 14,534,634 shares of the company’s stock worth $1,936,595,000 after acquiring an additional 369,918 shares in the last quarter. Parnassus Investments CA grew its stake in shares of Clorox by 1.7% in the third quarter. Parnassus Investments CA now owns 4,451,150 shares of the company’s stock valued at $587,151,000 after buying an additional 76,236 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Clorox by 5.3% in the second quarter. Wells Fargo & Company MN now owns 4,412,600 shares of the company’s stock valued at $587,934,000 after buying an additional 221,168 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Clorox by 24.5% in the second quarter. Renaissance Technologies LLC now owns 1,341,400 shares of the company’s stock valued at $178,728,000 after buying an additional 263,700 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Clorox by 24.6% in the second quarter. Ameriprise Financial Inc. now owns 1,341,272 shares of the company’s stock valued at $178,433,000 after buying an additional 265,200 shares in the last quarter. 73.42% of the stock is owned by institutional investors.

Clorox (CLX) traded up $1.37 during midday trading on Friday, reaching $147.63. The company had a trading volume of 1,061,788 shares, compared to its average volume of 833,080. Clorox has a twelve month low of $117.94 and a twelve month high of $148.23. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. The company has a market cap of $19,040.00, a PE ratio of 26.60, a price-to-earnings-growth ratio of 4.02 and a beta of 0.43.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Wednesday, January 24th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $3.36 annualized dividend and a dividend yield of 2.28%. Clorox’s dividend payout ratio is currently 61.65%.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Clorox Co (CLX) Will Announce Quarterly Sales of $1.43 Billion” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/17/zacks-analysts-expect-clorox-co-clx-will-announce-quarterly-sales-of-1-43-billion.html.

Clorox Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.